Skip to main content
. 2009 Apr;22(2):349–369. doi: 10.1128/CMR.00053-08

TABLE 5.

ETBF association with IBD or colorectal cancer

Reference (author, yr [reference no.]) Study design Location n ETBF diagnostic method Main results Limitations
Prindiville et al., 2000 (88) Endoscopy-based case series, with controls University of California, Davis, Sacramento, CA 101 patients with IBD or diarrhea, 69 controls Stool culture, HT29 cell assay, nested PCR for bft gene DNA extracted from stool 11/57 (19.3%) patients with active IBD were positive for ETBF by stool PCR vs 0/26 patients with inactive IBD (P < 0.01); 5/18 (27.8%) patients with diarrhea and 2/69 (2.9%) controls were ETBF positive by stool PCR (P < 0.0005); only 4.8% with IBD and 11% with diarrhea were ETBF positive by culture and HT29 cell assay Limited study design details, including source of controls; stools were frozen for 2 weeks prior to analysis by culture; B. fragilis isolation rates not reported
Bassett et al., 2004 (7) Endoscopy-based case series, with controls London, United Kingdom 35 patients with IBD and 37 controls; control population included 19 patients with culture-negative diarrhea and 18 patients without diarrhea, all of whom were being investigated by endoscopy for abdominal pain or changes in bowel habits Nested PCR for bft gene on DNA extracted from luminal washings or biopsies Of 60 patients with luminal washings available for analysis, 10/28 (35.7%) “controls” (6/14 with diarrhea and 4/14 without diarrhea) and 8/32 (25%) IBD patients were ETBF positive; 7/25 (28%) patients with active IBD and 1/7 (14.3%) patients with inactive IBD were ETBF positive (difference not significant); 4/32 (12.5%) IBD patients and 6/33 (18.2%) controls with colonic biopsies were ETBF positive Small study with limited details on control population; population defined as controls included patients with and without diarrhea; colonic biopsies and luminal washings were frozen for an unspecified time prior to analysis
Ulger et al., 2006 (113) Prospective, consecutive case series with concurrent controls Istanbul, Turkey 73 patients with colorectal cancer; 59 healthy controls (age and gender matched) Stool culture, PCR for bft gene on fecal B. fragilis isolates B. fragilis isolated from 77% of patients and 68% of controls (difference not significant); 21/56 (38%) patients and 5/40 (12%) controls were ETBF positive (P = 0.009) Small cross-sectional study without full colon cancer risk factor analysis